Abstract 1757O
Background
Tebentafusp (tebe), an investigational TCR–anti-CD3 bispecific fusion protein that targets gp100 and activates T cells, has shown OS benefit in 1st line mUM. OS was improved in patients (pts) regardless of RECISTv1.1 best response, suggesting better surrogate efficacy endpoints are needed.
Methods
2L+ HLA-A*02:01+ mUM pts were treated weekly with 68mcg tebe after intra-patient dose escalation (NCT02570308). RECISTv1.1 was assessed by an independent radiographic committee. Serum samples (N=118) collected at baseline (BL) and at weeks (wks) 5, 9 on tebe were analyzed for ctDNA using a targeted mPCR-NGS assay for mutations in 15 genes including mUM oncogenes GNAQ, GNA11, SF3B1, CYSLTR2, PLCB4 and EIF1AX. 0.1-3 log reductions in mean tumour molecules (MTM) per ml of serum observed on treatment were tested for association with OS.
Results
109/118 (92%) of pts had detectable ctDNA. MTM at BL was correlated with tumor burden as assessed by sum of longest diameters (Spearman’s r=0.61, P=10-10). By wk 9, in 99 pts with BL and on-treatment MTM measurements, any (>0) ctDNA reduction was observed in 69 (70%). In 97 pts that were evaluable by RECISTv1.1, any ctDNA reduction was observed in 31/48 with progressive disease (PD), 34/45 with stable disease (SD) and 2/4 with partial response (PR). Magnitude of ctDNA reduction by wk 9 was strongly associated with improvement in OS (R2=0.87, P<0.0001): 0.1 log reduction hazard ratio HR 0.8; 0.5 log reduction HR 0.5; 1 log reduction HR 0.4; 2 log reduction HR 0.3, 3 log reduction HR 0.2 and undetectable ctDNA (clearance) HR 0.1. 1 yr OS was 100% in pts with ctDNA clearance (N=14) vs 57% in those with increased ctDNA (N=30). Best overall response among those with ctDNA clearance was PD in 4 (29%), SD in 8 (57%) and PR in 1 (7%).
Conclusions
ctDNA was detected in most mUM pts, associated with tumor burden at BL and reduced in 70% of pts on tebe, despite a RECIST response rate of <10%. ctDNA reduction as early as 9 wks on tebe was strongly associated with improved OS, even in pts with RECIST PD or SD. Early ctDNA reduction may be a better surrogate of tebe efficacy than RECIST objective response in mUM.
Clinical trial identification
NCT02570308.
Editorial acknowledgement
Legal entity responsible for the study
Immunocore Ltd.
Funding
Immunocore Ltd.
Disclosure
A.N. Shoushtari: Financial Interests, Institutional, Research Grant: Immunocore Ltd.; Financial Interests, Institutional, Research Grant: BMS; Non-Financial Interests, Personal, Other: Castle Biosciences; Financial Interests, Institutional, Research Grant: Xcovery; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer. L. Collins: Financial Interests, Institutional, Full or part-time Employment: Immunocore Ltd. E. Espinosa: Non-Financial Interests, Personal, Advisory Role: BMS; Non-Financial Interests, Personal, Advisory Role: MSD; Non-Financial Interests, Personal, Advisory Role: Novartis; Non-Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Research Grant: Roche; Non-Financial Interests, Institutional, Principal Investigator: Immunocore. H. Sethi: Financial Interests, Institutional, Full or part-time Employment: Natera Inc.; Financial Interests, Institutional, Stocks/Shares: Natera Inc.. S. Stanhope: Financial Interests, Institutional, Full or part-time Employment: Immunocore Ltd. S. Abdullah: Financial Interests, Institutional, Full or part-time Employment: Immunocore Ltd. A. Ikeguchi: Non-Financial Interests, Institutional, Principal Investigator: Immunocore. K. Ranade: Financial Interests, Institutional, Full or part-time Employment: Immunocore Ltd. O. Hamid: Non-Financial Interests, Personal, Advisory Board: Aduro; Non-Financial Interests, Personal, Advisory Board: Akeso; Non-Financial Interests, Personal, Advisory Board: Amgen; Non-Financial Interests, Personal, Advisory Board: BeiGene; Non-Financial Interests, Personal, Advisory Board: Bioatla; Non-Financial Interests, Personal, Invited Speaker: BMS; Non-Financial Interests, Personal, Advisory Board: BMS; Non-Financial Interests, Personal, Advisory Board: GSK; Non-Financial Interests, Personal, Advisory Board: Idera; Non-Financial Interests, Personal, Advisory Board: Immunocore; Non-Financial Interests, Personal, Advisory Board: Incyte; Non-Financial Interests, Personal, Advisory Board: Janssen; Non-Financial Interests, Personal, Advisory Board: Merck; Non-Financial Interests, Personal, Advisory Board: Nextcure; Non-Financial Interests, Personal, Invited Speaker: Novartis; Non-Financial Interests, Personal, Advisory Board: Novartis; Non-Financial Interests, Personal, Invited Speaker: Pfizer; Non-Financial Interests, Personal, Advisory Board: Pfizer; Non-Financial Interests, Personal, Advisory Board: Roche Genentech; Non-Financial Interests, Personal, Advisory Board: Sanofi / Regeneron; Non-Financial Interests, Personal, Invited Speaker: Sanofi / Regeneron; Non-Financial Interests, Personal, Advisory Board: Seagen; Non-Financial Interests, Personal, Advisory Board: Tempus; Non-Financial Interests, Personal, Advisory Board: Zelluna; Non-Financial Interests, Institutional, Principal Investigator: Aduro; Non-Financial Interests, Institutional, Principal Investigator: Akeso; Non-Financial Interests, Institutional, Principal Investigator: Amgen; Non-Financial Interests, Institutional, Principal Investigator: Arcus; Non-Financial Interests, Institutional, Principal Investigator: Bioatla; Non-Financial Interests, Institutional, Principal Investigator: BMS; Non-Financial Interests, Institutional, Principal Investigator: CytomX; Non-Financial Interests, Institutional, Principal Investigator: Exelixis; Non-Financial Interests, Institutional, Principal Investigator: GSK; Non-Financial Interests, Institutional, Principal Investigator: Idera; Non-Financial Interests, Institutional, Principal Investigator: Immunocore; Non-Financial Interests, Institutional, Principal Investigator: Incyte; Non-Financial Interests, Institutional, Principal Investigator: Iovance; Non-Financial Interests, Institutional, Principal Investigator: Merck; Non-Financial Interests, Institutional, Principal Investigator: Merck Serono; Non-Financial Interests, Institutional, Principal Investigator: Moderna; Non-Financial Interests, Institutional, Principal Investigator: Nextcure; Non-Financial Interests, Institutional, Principal Investigator: Novartis; Non-Financial Interests, Institutional, Principal Investigator: Pfizer; Non-Financial Interests, Institutional, Principal Investigator: Roche Genentech; Non-Financial Interests, Institutional, Principal Investigator: Sanofi / Regeneron; Non-Financial Interests, Institutional, Principal Investigator: Seagen; Non-Financial Interests, Institutional, Principal Investigator: Torque; Non-Financial Interests, Institutional, Principal Investigator: Zelluna.
Resources from the same session
1758O - Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
Presenter: Kaysia Ludford
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
1124O - Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides
Presenter: Ingrid Garberis
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
1123O - Evaluation of cell-free DNA approaches for multi-cancer early detection
Presenter: Minetta Liu
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
Invited Discussant 1123O and 1757O
Presenter: Christian Rolfo
Session: Proffered Paper session - Translational research
Resources:
Webcast
Q&A and live discussion
Presenter: Christian Rolfo
Session: Proffered Paper session - Translational research
Resources:
Slides
Webcast
Invited Discussant 1758O and 1124O
Presenter: Sherene Loi
Session: Proffered Paper session - Translational research
Resources:
Webcast
Q&A and live discussion
Presenter: Sherene Loi
Session: Proffered Paper session - Translational research
Resources:
Slides
Webcast